BACKGROUND Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasin...BACKGROUND Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasing attention.CASE SUMMARY We treated three patients with acute cerebral infarction who died following treatment with edaravone.Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasing attention.CONCLUSION Our cases highlight the importance of educating clinicians regarding the new edaravone-induced clinical syndromes of cerebral infarction as potentially fatal adverse drug reactions.Considering that no laboratory or confirmatory test exists to diagnose edaravone-induced death from cerebral infarction,clinicians’knowledge is the key element in recognizing this phenomenon.展开更多
BACKGROUND:Edaravone(3-methyl-1-penyl-2-pyrazolin-5-one) is a potent free-radical scavenger and has the antioxidant ability to inhibit lipid peroxidation.The study aimed to examine the effect of edaravone on protectin...BACKGROUND:Edaravone(3-methyl-1-penyl-2-pyrazolin-5-one) is a potent free-radical scavenger and has the antioxidant ability to inhibit lipid peroxidation.The study aimed to examine the effect of edaravone on protecting the acute injury of human type II alveolar epithelial cells(A549cells) induced by paraquat(PQ) and the change of production of reactive oxygen species(ROS),malondialdehyde(MDA),superoxide dismutase(SOD).METHODS:A549 cells were cultured and divided into PQ group(group P),edaravone-treated group(group E) and normal control group(group C).The cells in group P were exposed to paraquat(600 umol/L),and the cells in group E were treated with edaravone(100 umol/L) additionally,and no drug intervention was given to the cells in group C.Real-time monitoring by LSCM was used to detect the cell response and the intracellular dynamic change of ROS level in A549 cells after administration of PQ and edaravone.And the levels of SOD and MDA were detected respectively by biochemistry colorimetry.Data were expressed as mean ± standard error of the mean.Statistical analysis was carried out with the soft SPSS 16.0.RESULTS:The concentration of intracellular ROS significantly increased when PQ was given to A549 cells.But after administration of edaravone,the concentration of intracellular ROS was decreased.Compared to the PQ group,the levels of SOD in the edaravone group were significantly increased while the levels of MDA were markedly decreased.CONCLUSIONS:Paraquat can increase the oxidative stress,and induce the lipid peroxidation of A549 cells.Edaravone has the effect to scavenge reactive oxygen species,and to protect against the PQ-induced lung toxicity.展开更多
BACKGROUND: Endoplasmic reticulum (ER) stress impairs ER functions and leads to the accumulation of unfolded or misfolded proteins in the ER lumen. ER stress-induced cell death plays an important role in cerebral isch...BACKGROUND: Endoplasmic reticulum (ER) stress impairs ER functions and leads to the accumulation of unfolded or misfolded proteins in the ER lumen. ER stress-induced cell death plays an important role in cerebral ischemia. Edaravon (3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent and novel scavenger of free radicals that inhibit delayed neuronal death, as demonstrated by in vitro and animal studies. However, its effect on ER stress and induced neuronal apoptosis in a rat model of brief middle cerebral artery occlusion remains unclear. OBJECTIVE: To explore the effects of edaravone on the expression of ER stress-related factors and neuronal apoptosis, based on the hypothesis that edaravone influences ER stress in a rat model of cerebral ischemia/reperfusion. DESIGN, TIME AND SETTING: A randomized, controlled, animal study was performed at the Laboratory of Department of Neurology, Xiangya Hospital and the Department of Laboratory Animals, Xiangya Medical College, Central South University in China from June 2005 to May 2006. MATERIALS: Edaravone was purchased from Simcere Pharmaceutical Group, China. METHODS: A total of 216 adult, male, Sprague Dawley rats were randomly assigned to sham-surgery, model and edaravone groups, with 72 rats in each group. Brief middle cerebral artery occlusion was established in the model and edaravone groups. In addition, the edaravone group rats were injected with 3 mg/kg edaravone through the tail vein. MAIN OUTCOME MEASURES: RNA-dependent protein kinase-like endoplasmic reticulum eukaryotic translation initiation factor 2α kinase (PERK) and C/EBP homology protein (CHOP) mRNA expression in the ischemic parietal cortex was determined by reverse transcription- polymerase chain reaction; phosphorylated PERK and CHOP protein expression was detected by immunohistochemistry; neuronal apoptosis was detected by TdT-mediated-dUTP nick end labeling. RESULTS: Neurological deficit scores were significantly reduced in the edaravone group compared to the model group at 12, 24, and 72 hours following reperfusion (P < 0.05). In addition, PERK and CHOP mRNA as well as phosphorylated PERK and CHOP protein expression were significantly reduced in the edaravone group compared to the model group at 1, 3, and 6 hours following reperfusion (P < 0.05, P < 0.01). CHOP mRNA expression was decreased in the edaravone group compared to the model group at 3, 6, 12, and 24 hours following reperfusion (P < 0.01), while CHOP protein expression was less than the model group at 6, 12, and 24 hours following reperfusion (P < 0.05). CONCLUSION: Edaravone treatment resulted in decreased PERK and CHOP expression following ischemia/reperfusion, as well as reduced neuronal apoptosis. Edaravone exhibited a neuroprotective role by inhibiting endoplasmic reticulum stress.展开更多
AIM: To evaluate the neuroprotective activity of systemically administered edaravone in early and late stage of experimental glaucoma in rats.METHODS: In this study, 60 Wistar albino rats were used. Experimental glauc...AIM: To evaluate the neuroprotective activity of systemically administered edaravone in early and late stage of experimental glaucoma in rats.METHODS: In this study, 60 Wistar albino rats were used. Experimental glaucoma model was created by injecting hyaluronic acid to the anterior chamber once a week for 6wk in 46 of 60 subjects. Fourteen subjects without any medication were included as control group.Edaravone administered intraperitoneally 3 mg/kg/d to the 15 of 30 subjects starting at the onset of glaucoma induction and also administered intraperitoneally3 mg/kg/d to the other 15 subjects starting at three weeks after the onset of glaucoma induction. The other16 subjects who underwent glaucoma induction was administered any therapy. Retinal ganglion cells(RGCs)have been marked with dextran tetramethylrhodamine(DTMR) retrograde at the end of the sixth week and after48 h, subjects were sacrificed by the method of cardiac perfusion. Alive RGC density was assessed in the wholemount retina. Whole-mount retinal tissues homogenized and nitric oxide(NO), malondialdehyde(MDA) and total antioxidant capacity(TAC) values were measured biochemically.RESULTS: RGCs counted with Image-Pro Plus program, in the treatment group were found to be statistically significantly protected, compared to the glaucoma group(Bonferroni,P <0.05). The neuroprotective activity of edaravone was found to be more influential byadministration at the start of the glaucoma process.Statistically significant lower NO levels were determined in the glaucoma group comparing treatment groups(Bonferroni, P <0.05). MDA levels were found to be highest in untreated glaucoma group, TAC levels were found to be lower in the glaucoma induction groups than the control group(Bonferroni, P <0.05).CONCLUSION: Systemic administration of edaravone in experimental glaucoma showed potent neuroprotective activity. The role of oxidative stress causing RGC damage in glaucoma was supported by this study results.展开更多
Objective:To systematically evaluate the effect of Xuesaitong injection combined with edaravone injection on hemorheology indexes in patients with acute cerebral infarction.Methods:Search CNKI,WanFang,VIP,SinoMed,PubM...Objective:To systematically evaluate the effect of Xuesaitong injection combined with edaravone injection on hemorheology indexes in patients with acute cerebral infarction.Methods:Search CNKI,WanFang,VIP,SinoMed,PubMed,Cochrane Library and other databases,collect randomized controlled trials(RCTs)of Xuesaitong combined with edaravone in the treatment of acute cerebral infarction from the establishment of the database to November 2020,using RevMan 5.3 software Perform Meta analysis.Results:10 RCTs were included,with a total of 834 patients,417 in the experimental group and 417 in the control group.The results of Meta analysis showed that the experimental group was better than the control group in improving the whole plasma viscosity(MD=-0.73,95%CI[-0.83,-0.63],P<0.00001);in terms of improving the thrombosis coefficient,the test group is better than the control group(MD=-0.19,95%CI[-0.22,-0.15],P<0.00001);In terms of platelet aggregation rate,the test group was better than the control group(MD=-0.21,95%CI[-0.25,-0.17],P<0.00001).GRADE systematically evaluates whole plasma viscosity,thrombosis coefficient,and platelet aggregation rate,showing that the level of evidence is low or very low,and the strength of the recommendation is weak.Conclusion:Xuesaitong injection combined with edaravone injection has relatively satisfactory results in improving hemorheology indexes in patients with acute cerebral infarction,and there is no obvious safety problem.However,due to the small number of included studies and the total sample size,and the limitation of the quality of the included original studies,the results of this study need to be designed with strict,high-quality,large-sample,multi-center,and more internationally recognized clinical outcome indicators and efficacy experiments to verify,in order to obtain stronger evidence-based medicine.展开更多
OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral ...OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral infarction. METHOSDS: A total of 76 patients with hemorrhagic cerebral infarction treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2017 to May 2018 were selected and were randomly divided into treatment group and control group, with 38 patients in each group. The control group was given edaravone, and the treatment group was given Maixuekang Capsules on the basis of the control group. The clinical efficacy, serum MMP-9 and S-100β protein levels, neurological function recovery, activity of daily living and incidence rate of adverse reactions were compared between the 2 groups. RESULTS: The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group(P < 0.05); the National Institutes of Health Stroke Scale(NIHSS) score in the 2 groups decreased(P < 0.05), and the Activity of Daily Living Scale(ADL) score increased(P < 0.05), the improvement of the above 2 scores in the treatment group were better than those in the control group(P < 0.05); the level of MMP-9 was gradually decreasing in the 2 groups, on the 7th day, 14 th day after treatment, and the levels of MMP-9 decreased significantly(P < 0.05), and the treatment group was lower than the control group at all time points(P < 0.05); on the 3rd day after treatment, the levels of S-100β protein in the 2 groups increased significantly(P < 0.05); on the 7th day, 14 th day after treatment, the levels of S-100β protein in the two groups decreased significantly(P < 0.05), and the treatment group was significantly lower than the control group(P < 0.05); there was no significant difference in incidence rate of adverse reactions between 7.89% in the control group and 5.26% in the treatment group(P > 0.05). CONCLUSION: The combination of Maixuekang Capsules and edaravone is effective in treating hemorrhagic cerebral infarction, and it can significantly improve neurological function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.展开更多
Objective:To explore the effect of low-repetitive transcranial magnetic stimulation (low-rTMS) in combined with edaravone on the inflammatory cytokines and cerebral metabolites in patients with cerebral infarction and...Objective:To explore the effect of low-repetitive transcranial magnetic stimulation (low-rTMS) in combined with edaravone on the inflammatory cytokines and cerebral metabolites in patients with cerebral infarction and aphasia.Methods:A total of 70 patients with acute cerebral infarction (ACI) and motor aphasia who were admitted in our hospital from March, 2015 to March, 2016 were included in the study and randomized into the observation group and the control group, 35 in each group. The patients in the control group were given blood pressure reduction, intracranial pressure reduction, blood lipid regulation, anti-platelet aggregation, symptomatic and supportive treatments, edaravone (30 mg) + normal saline (100 mL), ivdrip, 2 times/d, continuously for 2 weeks. On this basis, the patients in the observation group were given additional rTMS, continuously for 10 d. Hs-CRP, IL-6, IL-8, and TNF-α levels before treatment, 1 week and 2 weeks after treatment in the two groups were detected. MRS was used to detect NAA and Cho in Broca district before treatment, 1 week and 2 weeks after treatment in the two groups. ABC was used to evaluate the linguistic function before treatment, 2 weeks, 3 months, and 6 months in the two groups.Results:Hs-CRP, IL-6, IL-8, and TNF-α levels 1 week and 2 weeks after treatment in the observation group were significantly lower than those in the control group (P<0.05). NAA value on the left side 1 week and 2 weeks after treatment in the observation group was significantly higher than that in the control group (P<0.05), while Cho value was significantly lower than that in the control group (P<0.05). ABC score 2 weeks, 3 months, and 6 months after treatment in the observation group was significantly higher than that in the control group (P<0.05).Conclusions:Edaravone in combined with low-rTMS in the treatment of ACI can effectively inhibit the inflammatory reaction, improve the neurological deficit degree, and promote the recovery of cortex language neural network.展开更多
Objective: To investigate the effects of standardized three-stage rehabilitation combined with edaravone therapy on the neurotrophic state and oxidative stress injury in patients with cerebral infarction. Methods: A t...Objective: To investigate the effects of standardized three-stage rehabilitation combined with edaravone therapy on the neurotrophic state and oxidative stress injury in patients with cerebral infarction. Methods: A total of 90 patients with acute cerebral infarction who were treated in the hospital between May 2015 and April 2017 were divided into control group (n=45) and observation group (n=45) by random number table. Control group received edaravone therapy, and observation group received standardized three-stage rehabilitation combined with edaravone therapy. The differences in neurotrophic state and oxidative stress injury were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum levels of neurotrophic indexes and oxidative stress indexes between the two groups before treatment. After treatment, serum neurotrophic indexes BDNF and NGF levels of observation group were higher than those of control group;serum oxidation indexes AOPPs, LHP and MDA levels were lower than those of control group whereas SOD, CAT and T-AOC levels were higher than those of control group. Conclusion:Standardized three-stage rehabilitation combined with edaravone therapy can effectively optimize the neurotrophic state and inhibit the oxidative stress in patients with cerebral infarction.展开更多
Objective:To investigate the influence of edaravone on the expression of growth arrest and DNA damage-inducible protein 34(GADD34).Methods:A total of 108 healthy male Sprague-Dawlcy rats were randomly divided into sha...Objective:To investigate the influence of edaravone on the expression of growth arrest and DNA damage-inducible protein 34(GADD34).Methods:A total of 108 healthy male Sprague-Dawlcy rats were randomly divided into sham operation group,model group and edaravone.group(36 cases for each group).Transient focal cerebral ischemia was induced by middle cerebral artery occlusion for 2 h followed by reperfusion in Sprague-Dawlev rats.Then.GAOD34 expression was measured with immunohistochemistry at different time-points after reperfusion in the peri-infarct regions of all rats.Results:The GADD34 expression was detected in the peri-infaret regions of rats 1 h after reperfusion,which reached its peak 24 h after reperfusion.And edaravone could significantly down-regulate the GAOD34 expression.Conclusions:Edaravon could down-regulate GADD34 expression,which suggests that edaravone may exert an important function in inhibiting endoplasmic reticulum stress reaction by scavenging free radicals in the upper stream.展开更多
Background: Recently, it has become apparent that reactive oxygen species (ROS) play a critical role in the initiation of atherosclerosis. In this study, the effect of radical scavenger edaravone to the leukocyte roll...Background: Recently, it has become apparent that reactive oxygen species (ROS) play a critical role in the initiation of atherosclerosis. In this study, the effect of radical scavenger edaravone to the leukocyte rolling and to the expression of adhesion molecules on microvascular endothelium was investigated. Methods: DSS induced rat colitis model was used as an inflammation model. Edaravone (10.5 mg/kg, Mitsubishi Tanabe Pharma Corporation, Japan) was used to examine the action of ROS. Images of leukocyte rolling in mesenteric microvessels were investigated in a fluorescence bio-imaging model. Each cross section from the target blood vessel (aotic root, aorta, superior mesenteric artery) were examined by immune-peroxidase staining with anti-P-selectin, E-selectin, ICAM-1 antibody using the streptavidin/biotinylated horseradish peroxidase method. Results: 1) Leukocyte rolling in mesenteric microvessels was significantly increased in colitis. The number of rolling leukocyte was significantly decreased in edaravone group than placebo group (501.3 ± 39.2 vs 252.2 ± 37.2 count/100 μm/10 min). 2) The expression of P-selectin in endothelial cell was significantly increased in colitis. However, this expression was decreased in edaravone group. 3) The expression of E-selectin was not induced to intact aortic root and aorta. In the superior mesenteric artery, the expression was induced by inflammation, and it was attenuated by edaravone. 4) There was little expression of ICAM-1 in both intact aortic root and aortas. While, in the superior mesenteric artery, the expression was confirmed only in placebo group in colitis, and it was attenuated in edaravone group. Conclusions: It was suggested that administration of edaravone led to improving a haemostasis of microcirculation based on down-regulation of adhesion molecules. These results support the evidence that ROS plays a critical role in micro- vascular dysfunction.展开更多
Objective: To investigate the protective effects of the atomisation inhalation of edaravone on the lung tissues of rats with smoke inhalation injury. Methods: Forty male Sprague-Dawley (SD) rats were randomly divided ...Objective: To investigate the protective effects of the atomisation inhalation of edaravone on the lung tissues of rats with smoke inhalation injury. Methods: Forty male Sprague-Dawley (SD) rats were randomly divided into four groups of ten rats each: normal control group (group A), normal saline atomisation group (group B), edaravone aerosol group (group C) and edaravone atomisation prevention group (group D). Barring group A, the groups were used to create a model of severe smoke inhalation injury. However, before developing the model, group D rats were made to inhale edaravone (3.6 mg/mL) for 10 min. Six hours following smoke inhalation injury, abdominal artery blood samples were centrifuged, the lung tissue homogenate was prepared and carotid artery blood samples were used for blood gas analysis and oxygenation index (PaO<sub>2</sub>/FiO<sub>2</sub>) calculation. The levels of tumour necrosis factor alpha (TNF-α), interleukin (IL) 6 and IL-10 in serum and the levels of cysteine protease 3 (caspase-3), malondialdehyde (MDA), myeloperoxidase (MPO) and superoxide dismutase (SOD) in lung tissues were examined. The wet-dry ratio (W/D) and water content of the lung tissue were calculated, and the TUNEL method was used to determine the rate of lung tissue apoptosis in each group. Tissue specimens were obtained from the partial lung for histopathological examination. Results: Compared with those in group A, the water content of the lung tissue, the rate of lung tissue apoptosis, W/D and the caspase-3, TNF-α, IL-6, IL-10, MDA and MPO levels were significantly greater in other groups (PP< 0.05).<sup> </sup>Compared with those in group B, the levels of W/D, the water content of the lung tissue, the rate of lung tissue apoptosis and the levels of caspase-3, TNF-α, IL-6, MDA and MPO were significantly low (P and the levels of IL-10, SOD and PaO<sub>2</sub>/FiO<sub>2</sub> were significantly high in groups C and D (P The expression of the aforementioned factors was more evident in Group D (P < 0.05). Histopathological examination revealed that groups C and D had greater levels of inflammatory granulocytes than group B. This was more evident in group D. Conclusions: The inhalation of edaravone can reduce smoke inhalation-induced lung injury. This may be related to the inhibition of apoptosis, the reduction of peroxidation injury and the production/release of inflammatory mediators/free radicals. It exerts a remarkable preventive effect.展开更多
Objective:To study the effect of edaravone combined with cattle encephalon glycoside and ignotin injection adjuvant therapy on nerve function impairment in patients with severe craniocerebral injury.Methods: A total o...Objective:To study the effect of edaravone combined with cattle encephalon glycoside and ignotin injection adjuvant therapy on nerve function impairment in patients with severe craniocerebral injury.Methods: A total of 68 patients with severe craniocerebral injury who were treated in our hospital between January 2013 and May 2016 were collected and divided into control group and observation group according to the random number table, 34 cases in each group. Control group of patients received conventional + cattle encephalon glycoside and ignotin injection therapy, and observation group of patients received conventional +cattle encephalon glycoside and ignotin injection + edaravone therapy. The differences in serum levels of nerve injury indexes, oxidative stress indexes and inflammatory mediators were compared between the two groups of patients before and after treatment.Results: Before treatment, the differences in serum levels of nerve injury indexes, oxidative stress indexes and inflammatory mediators were not statistically significant between two groups of patients. After treatment, serum nerve injury index BNP level in observation group was higher than that in control group while S-100B, GFAP and NSE levels were lower than those in control group;serum oxidative stress indicators MDA and MPO levels were lower than those in control group while SOD and GSH-Px levels were higher than those in control group;serum inflammatory mediators IL-6, IL-8 and TNF-α levels were lower than those in control group.Conclusion:Edaravone combined with cattle encephalon glycoside and ignotin injection adjuvant therapy can effectively reduce the nerve function impairment in patients with severe craniocerebral injury, and the specific mechanisms are related to its effect on reducing the oxidative stress and inflammation.展开更多
Objective:To investigate the effects of minimally invasive craniotomy combined with edaravone on cerebral oxygen metabolism, cerebrovascular function and oxidative stress in patients with acute cerebral hemorrhage.Met...Objective:To investigate the effects of minimally invasive craniotomy combined with edaravone on cerebral oxygen metabolism, cerebrovascular function and oxidative stress in patients with acute cerebral hemorrhage.Methods:A total of 100 patients with acute cerebral hemorrhage treated in our hospital from March 2015 to February 2017 were randomly divided into control group and observation group. 50 patients in the control group were treated with minimally invasive craniotomy. On the basis of control group, patients in the observation group were treated with edaravone. Cerebral oxygen metabolism, cerebrovascular function and oxidative stress were measured later in both groups.Results:After treatment, the levels of SOD in both groups increased significantly and MDA levels decreased significantly, and SOD level in the observation group was (97.34±1.95) U/mL, which was significantly higher than the control group, MDA level was (2.77±0.11) mol/L and significantly lower than that of the control group after treatment;After treatment, the levels of ET in both groups were significantly lower than those before treatment, and the levels of CGRP were significantly higher than those before treatment. ET level in observation group was (3.24±0.22) μg/L after treatment, which was significantly lower than that in control group (59.67±0.79) pg/mL, which was significantly higher than the control group;After treatment, the levels of SjvO2, CjvO2 and PbtO2 in both groups were significantly increased compared with before treatment, the levels of Da-jvO2 and CEO2 were significantly lower than the level of before treatment, and the levels of SjvO2, The levels of CjvO2 and PbtO2 were (62.93±1.63)%, (99.31±0.94) mL/L and (28.56±1.55) mmHg, which were significantly higher than the control group. Da-jvO2 and CEO2 levels were (51.31±1.13) mL/L and (30.52±0.43)%, which were significantly lower than the control group.Conclusion: Edaravone combined with minimally invasive craniotomy can effectively reduce the level of oxidative stress, improve endothelial function and cerebral oxygen metabolism, and has reliable curative effect. It is worth further clinical application.展开更多
Objective:To investigate the effects of Bailing capsule combined with edaravone on immune function, antioxidant function and related factors in patients with chronic obstructive pulmonary disease (COPD).Methods:160 pa...Objective:To investigate the effects of Bailing capsule combined with edaravone on immune function, antioxidant function and related factors in patients with chronic obstructive pulmonary disease (COPD).Methods:160 patients with COPD who received treatment in the department of respiratory medicine of our hospital from March 2016 to March 2018 were randomly divided into control group and observation group, 80 cases in each group. Patients in the control group received edaravone treatment, while patients in the observation group received bailing capsule combined with edaravone treatment. The levels of T lymphocyte, superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α) and matrix metalloproteinase-9 (MMP-9) were measured and compared before and after treatment.Result: After treatment, the levels of CD3+, CD4+, CD4+ / CD8+, SOD and NO of patients in the control group and the observation group were significantly higher than those before treatment, while the levels of CD8+ and MDA were significantly lower than those before treatment. The change trend of the levels of T lymphocyte and antioxidant enzyme of patients in the observation group were significantly more obvious than that in the control group (P<0.05). After treatment, the serum levels of TGF-β1, TNF-α and MMP-9 of patients in the control group and the observation group decreased significantly, and the change trend of the above factors of patients in the observation group was more obvious than that in the control group (P<0.05).Conclusion: Bailing capsule combined with edaravone in the treatment of chronic obstructive pulmonary disease can significantly enhance the immune function and antioxidant function of patients and alleviate inflammation of the body. It has good clinical curative effect.展开更多
Objective: To investigate the effect of edaravone combined with hyperbaric oxygen therapy on cerebral vasculature, oxidative stress and inflammatory cytokines in patients with acute cerebral hemorrhage (ACH). Methods:...Objective: To investigate the effect of edaravone combined with hyperbaric oxygen therapy on cerebral vasculature, oxidative stress and inflammatory cytokines in patients with acute cerebral hemorrhage (ACH). Methods: A total of 96 patients with ACH were divided into control group (n=48) and observation group (n=48) according to the random number table. Both groups were treated routinely. On this basis, the control group was treated with edaravone injection, and the observation group was treated with edaravone injection combined with hyperbaric oxygen therapy. The change of cerebrovascular dynamics, oxidative stress products and inflammatory factors were examined in all subjects before and after treatment. Results: There were no significant differences in cerebrovascular function between the two groups before treatment. After treatment, the levels of Vmean and Qmean in both groups were significantly higher than those before treatment. The levels of Vmean and Qmean in the observation group were higher than those of the control group after treatment. There was no significant difference in serum oxidative stress between the two groups before treatment. After treatment, the levels of SOD in two groups were significantly higher than those before treatment. The level of SOD in the observation group was higher than that in the control group after treatment. After treatment, the levels of MDA in the two groups were significantly lower than that before treatment. The level of MDA in the observation group was lower than that of the control group after treatment. There were no significant differences in the level of serum inflammatory factors between the two groups before treatment. After treatment, the level of TNF-α and IL-1β in two groups were significantly lower than before treatment. The level of TNF-α and IL-1β in the observation group was lower than those of the control group after treatment. Conclusion:Edaravone combined with hyperbaric oxygen therapy can effectively improve cerebral vascular dynamics, reduce oxidative stress and inflammatory response in patients with ACH, which is beneficial to the prognosis of patients.展开更多
文摘BACKGROUND Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasing attention.CASE SUMMARY We treated three patients with acute cerebral infarction who died following treatment with edaravone.Edaravone is a widely used treatment for patients with cerebral infarction and,in most cases,edaravone-induced side effects are mild.However,edaravone-related adverse reactions have been receiving increasing attention.CONCLUSION Our cases highlight the importance of educating clinicians regarding the new edaravone-induced clinical syndromes of cerebral infarction as potentially fatal adverse drug reactions.Considering that no laboratory or confirmatory test exists to diagnose edaravone-induced death from cerebral infarction,clinicians’knowledge is the key element in recognizing this phenomenon.
基金supported by a grant form the Natural Science Foundation of China(Grant No.C030105)
文摘BACKGROUND:Edaravone(3-methyl-1-penyl-2-pyrazolin-5-one) is a potent free-radical scavenger and has the antioxidant ability to inhibit lipid peroxidation.The study aimed to examine the effect of edaravone on protecting the acute injury of human type II alveolar epithelial cells(A549cells) induced by paraquat(PQ) and the change of production of reactive oxygen species(ROS),malondialdehyde(MDA),superoxide dismutase(SOD).METHODS:A549 cells were cultured and divided into PQ group(group P),edaravone-treated group(group E) and normal control group(group C).The cells in group P were exposed to paraquat(600 umol/L),and the cells in group E were treated with edaravone(100 umol/L) additionally,and no drug intervention was given to the cells in group C.Real-time monitoring by LSCM was used to detect the cell response and the intracellular dynamic change of ROS level in A549 cells after administration of PQ and edaravone.And the levels of SOD and MDA were detected respectively by biochemistry colorimetry.Data were expressed as mean ± standard error of the mean.Statistical analysis was carried out with the soft SPSS 16.0.RESULTS:The concentration of intracellular ROS significantly increased when PQ was given to A549 cells.But after administration of edaravone,the concentration of intracellular ROS was decreased.Compared to the PQ group,the levels of SOD in the edaravone group were significantly increased while the levels of MDA were markedly decreased.CONCLUSIONS:Paraquat can increase the oxidative stress,and induce the lipid peroxidation of A549 cells.Edaravone has the effect to scavenge reactive oxygen species,and to protect against the PQ-induced lung toxicity.
文摘BACKGROUND: Endoplasmic reticulum (ER) stress impairs ER functions and leads to the accumulation of unfolded or misfolded proteins in the ER lumen. ER stress-induced cell death plays an important role in cerebral ischemia. Edaravon (3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent and novel scavenger of free radicals that inhibit delayed neuronal death, as demonstrated by in vitro and animal studies. However, its effect on ER stress and induced neuronal apoptosis in a rat model of brief middle cerebral artery occlusion remains unclear. OBJECTIVE: To explore the effects of edaravone on the expression of ER stress-related factors and neuronal apoptosis, based on the hypothesis that edaravone influences ER stress in a rat model of cerebral ischemia/reperfusion. DESIGN, TIME AND SETTING: A randomized, controlled, animal study was performed at the Laboratory of Department of Neurology, Xiangya Hospital and the Department of Laboratory Animals, Xiangya Medical College, Central South University in China from June 2005 to May 2006. MATERIALS: Edaravone was purchased from Simcere Pharmaceutical Group, China. METHODS: A total of 216 adult, male, Sprague Dawley rats were randomly assigned to sham-surgery, model and edaravone groups, with 72 rats in each group. Brief middle cerebral artery occlusion was established in the model and edaravone groups. In addition, the edaravone group rats were injected with 3 mg/kg edaravone through the tail vein. MAIN OUTCOME MEASURES: RNA-dependent protein kinase-like endoplasmic reticulum eukaryotic translation initiation factor 2α kinase (PERK) and C/EBP homology protein (CHOP) mRNA expression in the ischemic parietal cortex was determined by reverse transcription- polymerase chain reaction; phosphorylated PERK and CHOP protein expression was detected by immunohistochemistry; neuronal apoptosis was detected by TdT-mediated-dUTP nick end labeling. RESULTS: Neurological deficit scores were significantly reduced in the edaravone group compared to the model group at 12, 24, and 72 hours following reperfusion (P < 0.05). In addition, PERK and CHOP mRNA as well as phosphorylated PERK and CHOP protein expression were significantly reduced in the edaravone group compared to the model group at 1, 3, and 6 hours following reperfusion (P < 0.05, P < 0.01). CHOP mRNA expression was decreased in the edaravone group compared to the model group at 3, 6, 12, and 24 hours following reperfusion (P < 0.01), while CHOP protein expression was less than the model group at 6, 12, and 24 hours following reperfusion (P < 0.05). CONCLUSION: Edaravone treatment resulted in decreased PERK and CHOP expression following ischemia/reperfusion, as well as reduced neuronal apoptosis. Edaravone exhibited a neuroprotective role by inhibiting endoplasmic reticulum stress.
基金Supported by Kocaeli University Scientific Research Projects Unit(KOU-BAP:project No.2012/002)
文摘AIM: To evaluate the neuroprotective activity of systemically administered edaravone in early and late stage of experimental glaucoma in rats.METHODS: In this study, 60 Wistar albino rats were used. Experimental glaucoma model was created by injecting hyaluronic acid to the anterior chamber once a week for 6wk in 46 of 60 subjects. Fourteen subjects without any medication were included as control group.Edaravone administered intraperitoneally 3 mg/kg/d to the 15 of 30 subjects starting at the onset of glaucoma induction and also administered intraperitoneally3 mg/kg/d to the other 15 subjects starting at three weeks after the onset of glaucoma induction. The other16 subjects who underwent glaucoma induction was administered any therapy. Retinal ganglion cells(RGCs)have been marked with dextran tetramethylrhodamine(DTMR) retrograde at the end of the sixth week and after48 h, subjects were sacrificed by the method of cardiac perfusion. Alive RGC density was assessed in the wholemount retina. Whole-mount retinal tissues homogenized and nitric oxide(NO), malondialdehyde(MDA) and total antioxidant capacity(TAC) values were measured biochemically.RESULTS: RGCs counted with Image-Pro Plus program, in the treatment group were found to be statistically significantly protected, compared to the glaucoma group(Bonferroni,P <0.05). The neuroprotective activity of edaravone was found to be more influential byadministration at the start of the glaucoma process.Statistically significant lower NO levels were determined in the glaucoma group comparing treatment groups(Bonferroni, P <0.05). MDA levels were found to be highest in untreated glaucoma group, TAC levels were found to be lower in the glaucoma induction groups than the control group(Bonferroni, P <0.05).CONCLUSION: Systemic administration of edaravone in experimental glaucoma showed potent neuroprotective activity. The role of oxidative stress causing RGC damage in glaucoma was supported by this study results.
基金National Natural Science Foundation of China(No.81573926,No.81173235)Fundamental Research Funds for the Central Universities(No.2019-JYB-TD-003)。
文摘Objective:To systematically evaluate the effect of Xuesaitong injection combined with edaravone injection on hemorheology indexes in patients with acute cerebral infarction.Methods:Search CNKI,WanFang,VIP,SinoMed,PubMed,Cochrane Library and other databases,collect randomized controlled trials(RCTs)of Xuesaitong combined with edaravone in the treatment of acute cerebral infarction from the establishment of the database to November 2020,using RevMan 5.3 software Perform Meta analysis.Results:10 RCTs were included,with a total of 834 patients,417 in the experimental group and 417 in the control group.The results of Meta analysis showed that the experimental group was better than the control group in improving the whole plasma viscosity(MD=-0.73,95%CI[-0.83,-0.63],P<0.00001);in terms of improving the thrombosis coefficient,the test group is better than the control group(MD=-0.19,95%CI[-0.22,-0.15],P<0.00001);In terms of platelet aggregation rate,the test group was better than the control group(MD=-0.21,95%CI[-0.25,-0.17],P<0.00001).GRADE systematically evaluates whole plasma viscosity,thrombosis coefficient,and platelet aggregation rate,showing that the level of evidence is low or very low,and the strength of the recommendation is weak.Conclusion:Xuesaitong injection combined with edaravone injection has relatively satisfactory results in improving hemorheology indexes in patients with acute cerebral infarction,and there is no obvious safety problem.However,due to the small number of included studies and the total sample size,and the limitation of the quality of the included original studies,the results of this study need to be designed with strict,high-quality,large-sample,multi-center,and more internationally recognized clinical outcome indicators and efficacy experiments to verify,in order to obtain stronger evidence-based medicine.
文摘OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9(MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral infarction. METHOSDS: A total of 76 patients with hemorrhagic cerebral infarction treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2017 to May 2018 were selected and were randomly divided into treatment group and control group, with 38 patients in each group. The control group was given edaravone, and the treatment group was given Maixuekang Capsules on the basis of the control group. The clinical efficacy, serum MMP-9 and S-100β protein levels, neurological function recovery, activity of daily living and incidence rate of adverse reactions were compared between the 2 groups. RESULTS: The total effective rate of the treatment group was 92.11%, which was higher than 71.05% of the control group(P < 0.05); the National Institutes of Health Stroke Scale(NIHSS) score in the 2 groups decreased(P < 0.05), and the Activity of Daily Living Scale(ADL) score increased(P < 0.05), the improvement of the above 2 scores in the treatment group were better than those in the control group(P < 0.05); the level of MMP-9 was gradually decreasing in the 2 groups, on the 7th day, 14 th day after treatment, and the levels of MMP-9 decreased significantly(P < 0.05), and the treatment group was lower than the control group at all time points(P < 0.05); on the 3rd day after treatment, the levels of S-100β protein in the 2 groups increased significantly(P < 0.05); on the 7th day, 14 th day after treatment, the levels of S-100β protein in the two groups decreased significantly(P < 0.05), and the treatment group was significantly lower than the control group(P < 0.05); there was no significant difference in incidence rate of adverse reactions between 7.89% in the control group and 5.26% in the treatment group(P > 0.05). CONCLUSION: The combination of Maixuekang Capsules and edaravone is effective in treating hemorrhagic cerebral infarction, and it can significantly improve neurological function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.
文摘Objective:To explore the effect of low-repetitive transcranial magnetic stimulation (low-rTMS) in combined with edaravone on the inflammatory cytokines and cerebral metabolites in patients with cerebral infarction and aphasia.Methods:A total of 70 patients with acute cerebral infarction (ACI) and motor aphasia who were admitted in our hospital from March, 2015 to March, 2016 were included in the study and randomized into the observation group and the control group, 35 in each group. The patients in the control group were given blood pressure reduction, intracranial pressure reduction, blood lipid regulation, anti-platelet aggregation, symptomatic and supportive treatments, edaravone (30 mg) + normal saline (100 mL), ivdrip, 2 times/d, continuously for 2 weeks. On this basis, the patients in the observation group were given additional rTMS, continuously for 10 d. Hs-CRP, IL-6, IL-8, and TNF-α levels before treatment, 1 week and 2 weeks after treatment in the two groups were detected. MRS was used to detect NAA and Cho in Broca district before treatment, 1 week and 2 weeks after treatment in the two groups. ABC was used to evaluate the linguistic function before treatment, 2 weeks, 3 months, and 6 months in the two groups.Results:Hs-CRP, IL-6, IL-8, and TNF-α levels 1 week and 2 weeks after treatment in the observation group were significantly lower than those in the control group (P<0.05). NAA value on the left side 1 week and 2 weeks after treatment in the observation group was significantly higher than that in the control group (P<0.05), while Cho value was significantly lower than that in the control group (P<0.05). ABC score 2 weeks, 3 months, and 6 months after treatment in the observation group was significantly higher than that in the control group (P<0.05).Conclusions:Edaravone in combined with low-rTMS in the treatment of ACI can effectively inhibit the inflammatory reaction, improve the neurological deficit degree, and promote the recovery of cortex language neural network.
文摘Objective: To investigate the effects of standardized three-stage rehabilitation combined with edaravone therapy on the neurotrophic state and oxidative stress injury in patients with cerebral infarction. Methods: A total of 90 patients with acute cerebral infarction who were treated in the hospital between May 2015 and April 2017 were divided into control group (n=45) and observation group (n=45) by random number table. Control group received edaravone therapy, and observation group received standardized three-stage rehabilitation combined with edaravone therapy. The differences in neurotrophic state and oxidative stress injury were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum levels of neurotrophic indexes and oxidative stress indexes between the two groups before treatment. After treatment, serum neurotrophic indexes BDNF and NGF levels of observation group were higher than those of control group;serum oxidation indexes AOPPs, LHP and MDA levels were lower than those of control group whereas SOD, CAT and T-AOC levels were higher than those of control group. Conclusion:Standardized three-stage rehabilitation combined with edaravone therapy can effectively optimize the neurotrophic state and inhibit the oxidative stress in patients with cerebral infarction.
基金Supported by Clinical Special Funds of Chinese University Medical Journals.China(Grant No:11321937)
文摘Objective:To investigate the influence of edaravone on the expression of growth arrest and DNA damage-inducible protein 34(GADD34).Methods:A total of 108 healthy male Sprague-Dawlcy rats were randomly divided into sham operation group,model group and edaravone.group(36 cases for each group).Transient focal cerebral ischemia was induced by middle cerebral artery occlusion for 2 h followed by reperfusion in Sprague-Dawlev rats.Then.GAOD34 expression was measured with immunohistochemistry at different time-points after reperfusion in the peri-infarct regions of all rats.Results:The GADD34 expression was detected in the peri-infaret regions of rats 1 h after reperfusion,which reached its peak 24 h after reperfusion.And edaravone could significantly down-regulate the GAOD34 expression.Conclusions:Edaravon could down-regulate GADD34 expression,which suggests that edaravone may exert an important function in inhibiting endoplasmic reticulum stress reaction by scavenging free radicals in the upper stream.
文摘Background: Recently, it has become apparent that reactive oxygen species (ROS) play a critical role in the initiation of atherosclerosis. In this study, the effect of radical scavenger edaravone to the leukocyte rolling and to the expression of adhesion molecules on microvascular endothelium was investigated. Methods: DSS induced rat colitis model was used as an inflammation model. Edaravone (10.5 mg/kg, Mitsubishi Tanabe Pharma Corporation, Japan) was used to examine the action of ROS. Images of leukocyte rolling in mesenteric microvessels were investigated in a fluorescence bio-imaging model. Each cross section from the target blood vessel (aotic root, aorta, superior mesenteric artery) were examined by immune-peroxidase staining with anti-P-selectin, E-selectin, ICAM-1 antibody using the streptavidin/biotinylated horseradish peroxidase method. Results: 1) Leukocyte rolling in mesenteric microvessels was significantly increased in colitis. The number of rolling leukocyte was significantly decreased in edaravone group than placebo group (501.3 ± 39.2 vs 252.2 ± 37.2 count/100 μm/10 min). 2) The expression of P-selectin in endothelial cell was significantly increased in colitis. However, this expression was decreased in edaravone group. 3) The expression of E-selectin was not induced to intact aortic root and aorta. In the superior mesenteric artery, the expression was induced by inflammation, and it was attenuated by edaravone. 4) There was little expression of ICAM-1 in both intact aortic root and aortas. While, in the superior mesenteric artery, the expression was confirmed only in placebo group in colitis, and it was attenuated in edaravone group. Conclusions: It was suggested that administration of edaravone led to improving a haemostasis of microcirculation based on down-regulation of adhesion molecules. These results support the evidence that ROS plays a critical role in micro- vascular dysfunction.
文摘Objective: To investigate the protective effects of the atomisation inhalation of edaravone on the lung tissues of rats with smoke inhalation injury. Methods: Forty male Sprague-Dawley (SD) rats were randomly divided into four groups of ten rats each: normal control group (group A), normal saline atomisation group (group B), edaravone aerosol group (group C) and edaravone atomisation prevention group (group D). Barring group A, the groups were used to create a model of severe smoke inhalation injury. However, before developing the model, group D rats were made to inhale edaravone (3.6 mg/mL) for 10 min. Six hours following smoke inhalation injury, abdominal artery blood samples were centrifuged, the lung tissue homogenate was prepared and carotid artery blood samples were used for blood gas analysis and oxygenation index (PaO<sub>2</sub>/FiO<sub>2</sub>) calculation. The levels of tumour necrosis factor alpha (TNF-α), interleukin (IL) 6 and IL-10 in serum and the levels of cysteine protease 3 (caspase-3), malondialdehyde (MDA), myeloperoxidase (MPO) and superoxide dismutase (SOD) in lung tissues were examined. The wet-dry ratio (W/D) and water content of the lung tissue were calculated, and the TUNEL method was used to determine the rate of lung tissue apoptosis in each group. Tissue specimens were obtained from the partial lung for histopathological examination. Results: Compared with those in group A, the water content of the lung tissue, the rate of lung tissue apoptosis, W/D and the caspase-3, TNF-α, IL-6, IL-10, MDA and MPO levels were significantly greater in other groups (PP< 0.05).<sup> </sup>Compared with those in group B, the levels of W/D, the water content of the lung tissue, the rate of lung tissue apoptosis and the levels of caspase-3, TNF-α, IL-6, MDA and MPO were significantly low (P and the levels of IL-10, SOD and PaO<sub>2</sub>/FiO<sub>2</sub> were significantly high in groups C and D (P The expression of the aforementioned factors was more evident in Group D (P < 0.05). Histopathological examination revealed that groups C and D had greater levels of inflammatory granulocytes than group B. This was more evident in group D. Conclusions: The inhalation of edaravone can reduce smoke inhalation-induced lung injury. This may be related to the inhibition of apoptosis, the reduction of peroxidation injury and the production/release of inflammatory mediators/free radicals. It exerts a remarkable preventive effect.
文摘Objective:To study the effect of edaravone combined with cattle encephalon glycoside and ignotin injection adjuvant therapy on nerve function impairment in patients with severe craniocerebral injury.Methods: A total of 68 patients with severe craniocerebral injury who were treated in our hospital between January 2013 and May 2016 were collected and divided into control group and observation group according to the random number table, 34 cases in each group. Control group of patients received conventional + cattle encephalon glycoside and ignotin injection therapy, and observation group of patients received conventional +cattle encephalon glycoside and ignotin injection + edaravone therapy. The differences in serum levels of nerve injury indexes, oxidative stress indexes and inflammatory mediators were compared between the two groups of patients before and after treatment.Results: Before treatment, the differences in serum levels of nerve injury indexes, oxidative stress indexes and inflammatory mediators were not statistically significant between two groups of patients. After treatment, serum nerve injury index BNP level in observation group was higher than that in control group while S-100B, GFAP and NSE levels were lower than those in control group;serum oxidative stress indicators MDA and MPO levels were lower than those in control group while SOD and GSH-Px levels were higher than those in control group;serum inflammatory mediators IL-6, IL-8 and TNF-α levels were lower than those in control group.Conclusion:Edaravone combined with cattle encephalon glycoside and ignotin injection adjuvant therapy can effectively reduce the nerve function impairment in patients with severe craniocerebral injury, and the specific mechanisms are related to its effect on reducing the oxidative stress and inflammation.
基金This study was supported by National Natural Science Foundation(81371345).
文摘Objective:To investigate the effects of minimally invasive craniotomy combined with edaravone on cerebral oxygen metabolism, cerebrovascular function and oxidative stress in patients with acute cerebral hemorrhage.Methods:A total of 100 patients with acute cerebral hemorrhage treated in our hospital from March 2015 to February 2017 were randomly divided into control group and observation group. 50 patients in the control group were treated with minimally invasive craniotomy. On the basis of control group, patients in the observation group were treated with edaravone. Cerebral oxygen metabolism, cerebrovascular function and oxidative stress were measured later in both groups.Results:After treatment, the levels of SOD in both groups increased significantly and MDA levels decreased significantly, and SOD level in the observation group was (97.34±1.95) U/mL, which was significantly higher than the control group, MDA level was (2.77±0.11) mol/L and significantly lower than that of the control group after treatment;After treatment, the levels of ET in both groups were significantly lower than those before treatment, and the levels of CGRP were significantly higher than those before treatment. ET level in observation group was (3.24±0.22) μg/L after treatment, which was significantly lower than that in control group (59.67±0.79) pg/mL, which was significantly higher than the control group;After treatment, the levels of SjvO2, CjvO2 and PbtO2 in both groups were significantly increased compared with before treatment, the levels of Da-jvO2 and CEO2 were significantly lower than the level of before treatment, and the levels of SjvO2, The levels of CjvO2 and PbtO2 were (62.93±1.63)%, (99.31±0.94) mL/L and (28.56±1.55) mmHg, which were significantly higher than the control group. Da-jvO2 and CEO2 levels were (51.31±1.13) mL/L and (30.52±0.43)%, which were significantly lower than the control group.Conclusion: Edaravone combined with minimally invasive craniotomy can effectively reduce the level of oxidative stress, improve endothelial function and cerebral oxygen metabolism, and has reliable curative effect. It is worth further clinical application.
文摘Objective:To investigate the effects of Bailing capsule combined with edaravone on immune function, antioxidant function and related factors in patients with chronic obstructive pulmonary disease (COPD).Methods:160 patients with COPD who received treatment in the department of respiratory medicine of our hospital from March 2016 to March 2018 were randomly divided into control group and observation group, 80 cases in each group. Patients in the control group received edaravone treatment, while patients in the observation group received bailing capsule combined with edaravone treatment. The levels of T lymphocyte, superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), transforming growth factor-β1 (TGF-β1), tumor necrosis factor-α (TNF-α) and matrix metalloproteinase-9 (MMP-9) were measured and compared before and after treatment.Result: After treatment, the levels of CD3+, CD4+, CD4+ / CD8+, SOD and NO of patients in the control group and the observation group were significantly higher than those before treatment, while the levels of CD8+ and MDA were significantly lower than those before treatment. The change trend of the levels of T lymphocyte and antioxidant enzyme of patients in the observation group were significantly more obvious than that in the control group (P<0.05). After treatment, the serum levels of TGF-β1, TNF-α and MMP-9 of patients in the control group and the observation group decreased significantly, and the change trend of the above factors of patients in the observation group was more obvious than that in the control group (P<0.05).Conclusion: Bailing capsule combined with edaravone in the treatment of chronic obstructive pulmonary disease can significantly enhance the immune function and antioxidant function of patients and alleviate inflammation of the body. It has good clinical curative effect.
文摘Objective: To investigate the effect of edaravone combined with hyperbaric oxygen therapy on cerebral vasculature, oxidative stress and inflammatory cytokines in patients with acute cerebral hemorrhage (ACH). Methods: A total of 96 patients with ACH were divided into control group (n=48) and observation group (n=48) according to the random number table. Both groups were treated routinely. On this basis, the control group was treated with edaravone injection, and the observation group was treated with edaravone injection combined with hyperbaric oxygen therapy. The change of cerebrovascular dynamics, oxidative stress products and inflammatory factors were examined in all subjects before and after treatment. Results: There were no significant differences in cerebrovascular function between the two groups before treatment. After treatment, the levels of Vmean and Qmean in both groups were significantly higher than those before treatment. The levels of Vmean and Qmean in the observation group were higher than those of the control group after treatment. There was no significant difference in serum oxidative stress between the two groups before treatment. After treatment, the levels of SOD in two groups were significantly higher than those before treatment. The level of SOD in the observation group was higher than that in the control group after treatment. After treatment, the levels of MDA in the two groups were significantly lower than that before treatment. The level of MDA in the observation group was lower than that of the control group after treatment. There were no significant differences in the level of serum inflammatory factors between the two groups before treatment. After treatment, the level of TNF-α and IL-1β in two groups were significantly lower than before treatment. The level of TNF-α and IL-1β in the observation group was lower than those of the control group after treatment. Conclusion:Edaravone combined with hyperbaric oxygen therapy can effectively improve cerebral vascular dynamics, reduce oxidative stress and inflammatory response in patients with ACH, which is beneficial to the prognosis of patients.
